Intervacc AB

Intervacc AB is a biotechnology company based in Sweden that focuses on developing a new generation of vaccines within animal health. The company's slogan, "A new generation of vaccines based on fusions of recombinant proteins," captures its innovative approach to vaccine development. Since its founding in 2001, Intervacc AB has been at the forefront of creating vaccines based on recombinant proteins to address the growing demand for effective and safe vaccines in animal healthcare. The company's commitment to leveraging recombinant proteins in vaccine development aligns with the increasing emphasis on safety and efficacy in the healthcare industry. This approach positions Intervacc AB at the intersection of biotechnology, health care, and pharmaceutical industries, indicating the potential for significant impact and growth. Recently, Intervacc AB received a grant investment from Vinnova on 17 August 2023, underscoring the confidence of investors in the company's innovative vaccine technologies. This investment not only provides financial support but also signifies external validation of the company's potential to make a meaningful contribution to animal health care. Overall, Intervacc AB's focus on developing vaccines based on recombinant proteins, coupled with its recent grant investment, positions the company as an exciting player in the biotechnology and animal health sectors. With a strong emphasis on safety and effectiveness, Intervacc AB is poised to make a significant impact on animal health and the broader pharmaceutical industry.